Angela Stoddart, Ph.D.
Research Associate Professor
Dr. Stoddart received her B.S. and Ph.D. degrees from the University of Toronto. As an Immunology Ph.D. student in the laboratory of Dr. Chris Paige she studied the process of B cell commitment and cloned the gene encoding a sialic acid specific 9-O acetylesterase and characterized the expression of the sialic acid-binding lectin CD22, whose interactions are modified by 9-O-acetylation. In her post-doctoral work at the University of California San Francisco in Dr. Frances Brodsky’s lab, she showed that signaling in lipid rafts is integrated with clathrin-mediated endocytosis. Working in Dr. Michelle LeBeau’s lab at the University of Chicago, she received grants from the Leukemia & Lymphoma, Cancer Research and Lauri Strauss Leukemia foundations to develop a working mouse model of AML with the recurring translocation t(10;11) (p13;q14), involving the fusion of the MLLT10/AF10 gene with the PICAM gene, a clathrin assembly protein.
In 2010, Angela assumed responsibility for overseeing the research on therapy-related myeloid neoplasms (t-MNs) conducted under the auspices of Dr. LeBeau’s NCI-funded grants. During this time, she contributed to many seminal findings in del(5q) t-MN including the development of a mouse model of del(5q) AML and demonstration that haploinsufficient loss of more than one del(5q) gene contribute to disease progression. She showed that myeloid disease can be prevented by modulating WNT signaling in the bone marrow niche and that prior cytotoxic therapy induces senescence in the cells of the niche and contributes to malignant transformation. In Dr. McNerney’s lab, she is using her expertise to continue understanding the mechanisms leading to therapy-related myeloid disease with an eye towards clinical translation.